NasdaqGS:SANABiotechs
Assessing Sana Biotechnology (SANA) Valuation As Analyst Downgrade And FDA Scrutiny Weigh On Sentiment
Why sentiment has turned cautious on Sana Biotechnology (SANA)
Sana Biotechnology (SANA) has come under pressure after a recent analyst downgrade, just as the FDA increases regulatory scrutiny on gene therapies, putting extra focus on the company’s upcoming quarterly results and cash position.
See our latest analysis for Sana Biotechnology.
At a share price of US$3.85, Sana’s recent 30 day share price return of 15.94% and year to date share price return of 8.11% contrast with a 1 year total...